These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

57 related items for PubMed ID: 24490599

  • 1. Sequential therapies in castration-resistant prostate cancer.
    Buonerba C, Di Lorenzo G.
    Future Oncol; 2014 Feb; 10(2):153-5. PubMed ID: 24490599
    [No Abstract] [Full Text] [Related]

  • 2. Current, new and novel therapy for castration-resistant prostate cancer.
    Gaya JM, Ahallal Y, Sanchez-Salas R, Barret E, Rozet F, Galiano M, Macek P, Durand M, Cerruti J, Prapotnich D, Ropert S, Bennamoun M, Cathelineau X.
    Expert Rev Anticancer Ther; 2013 Jul; 13(7):819-27. PubMed ID: 23875660
    [Abstract] [Full Text] [Related]

  • 3. Should the Urologist Treat Castration Resistant Prostate Cancer? No.
    Petrylak DP.
    J Urol; 2015 Aug; 194(2):286-7. PubMed ID: 25986508
    [No Abstract] [Full Text] [Related]

  • 4. Should the Urologist Treat Castration Resistant Prostate Cancer? Yes.
    Wirth MP, Froehner M.
    J Urol; 2015 Aug; 194(2):286. PubMed ID: 25986513
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel.
    Fitzpatrick JM, Bellmunt J, Fizazi K, Heidenreich A, Sternberg CN, Tombal B, Alcaraz A, Bahl A, Bracarda S, Di Lorenzo G, Efstathiou E, Finn SP, Fosså S, Gillessen S, Kellokumpu-Lehtinen PL, Lecouvet FE, Oudard S, de Reijke TM, Robson CN, De Santis M, Seruga B, de Wit R.
    Eur J Cancer; 2014 Jun; 50(9):1617-27. PubMed ID: 24703899
    [Abstract] [Full Text] [Related]

  • 8. Clinical trial risk in castration-resistant prostate cancer: immunotherapies show promise.
    Tenuta A, Klotz L, Parker JL.
    BJU Int; 2014 May; 113(5b):E82-9. PubMed ID: 24053150
    [Abstract] [Full Text] [Related]

  • 9. [New era of the treatment of CRPC in Japan].
    Akaza H.
    Gan To Kagaku Ryoho; 2014 Jul; 41(7):804. PubMed ID: 25131863
    [Abstract] [Full Text] [Related]

  • 10. Non-metastatic castration-resistant prostate cancer (CPRCM0), an old scenario with renewed clinical interest.
    Morote J, Planas J, Maldonado X, Carles J.
    Actas Urol Esp; 2014 Sep; 38(7):419-20. PubMed ID: 24866537
    [No Abstract] [Full Text] [Related]

  • 11. Long noncoding RNA MALAT-1 is a new potential therapeutic target for castration resistant prostate cancer.
    Ren S, Liu Y, Xu W, Sun Y, Lu J, Wang F, Wei M, Shen J, Hou J, Gao X, Xu C, Huang J, Zhao Y, Sun Y.
    J Urol; 2013 Dec; 190(6):2278-87. PubMed ID: 23845456
    [Abstract] [Full Text] [Related]

  • 12. Dual PI3K/mTOR inhibitor NVP-BEZ235 sensitizes docetaxel in castration resistant prostate cancer.
    Yasumizu Y, Miyajima A, Kosaka T, Miyazaki Y, Kikuchi E, Oya M.
    J Urol; 2014 Jan; 191(1):227-34. PubMed ID: 23954373
    [Abstract] [Full Text] [Related]

  • 13. A Multitargeted Treatment Approach for Anemia and Cachexia in Metastatic Castration-Resistant Prostate Cancer.
    Macciò A, Gramignano G, Madeddu C.
    J Pain Symptom Manage; 2015 Aug; 50(2):e1-4. PubMed ID: 26004402
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Optimal treatment for castration-resistant prostate cancer.
    Izumi K, Namiki M.
    Asian J Androl; 2014 Aug; 16(3):498. PubMed ID: 24759581
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Renal impairment in prostate cancer: A close look is important.
    Naronha V, Pinninti R, Joshi A, Prabhash K.
    Indian J Cancer; 2015 Aug; 52(1):113. PubMed ID: 26837995
    [No Abstract] [Full Text] [Related]

  • 18. Precision, complexity and stigma in advanced prostate cancer terminology: it is time to move away from 'castration-resistant' prostate cancer.
    Pezaro CJ, Omlin A, Mastris K, ANZUP Consumer Advisory Panel, Attard G, Beer TM, Chi KN, Chowdhury S, Davis ID, Drake CG, de Bono JS, Efstathiou E, Gravis G, Higano CS, Hussain M, James N, Logothetis CJ, Morgans A, Parker C, Ryan CJ, Saad F, Sartor O, Small EJ, Sternberg CN, Sweeney CJ, Tannock I, Tombal B, Gillessen S.
    Ann Oncol; 2017 Aug 01; 28(8):1692-1694. PubMed ID: 28838209
    [No Abstract] [Full Text] [Related]

  • 19. [Hope for a new treatment for castration-resistant prostate cancer].
    Terzic J, Metzger D.
    Med Sci (Paris); 2023 Oct 01; 39(10):709-711. PubMed ID: 37943128
    [No Abstract] [Full Text] [Related]

  • 20. Cabozantinib: a novel agent with a dual mechanism of action for castration-resistant prostate carcinoma.
    Pinto A.
    Cancer Chemother Pharmacol; 2014 Feb 01; 73(2):219-22. PubMed ID: 24202668
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 3.